

| 规格 | 价格 | 会员价 | 库存 | 数量 | |||
|---|---|---|---|---|---|---|---|
| {[ item.pr_size ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb_sale, 1,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]} {[ getRatePriceInt(item.pr_rmb,item.pr_rate,1) ]} {[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} |
{[ getRatePriceInt(item.pr_rmb, 1,1) ]}{[ suihuo_tips(item.pr_tag_price, item.pr_am) ]} | {[ getRatePrice(item.pr_rmb_sale, 1,1,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,item.pr_rate,item.mem_rate,item.mem_isinteger) ]} {[ getRatePrice(item.pr_rmb,1,item.mem_rate,item.mem_isinteger) ]} | 现货 | 1周 咨询 | - + |
快速发货 顺丰冷链运输,1-2 天到达
品质保证
技术支持
免费溶解

| 产品名称 | p53 ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Pifithrin-μ | ✔ | 99%+ | |||||||||||||||||
| Pifithrin-α HBr | ✔ | 98% | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 产品名称 | Autophagy ↓ ↑ | 其他靶点 | 纯度 | ||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| SBI-0206965 |
+++
ULK2, IC50: 711 nM ULK1, IC50: 108 nM |
95% | |||||||||||||||||
| Hydroxychloroquine sulfate | ✔ | 99% | |||||||||||||||||
| Valproic acid sodium | ✔ | HDAC | 97% | ||||||||||||||||
| PFK-015 |
++
PFKFB3, IC50: 207 nM |
99%+ | |||||||||||||||||
| MRT68921 HCl |
++++
ULK2, IC50: 1.1 nM ULK1, IC50: 2.9 nM |
99%+ | |||||||||||||||||
| ROC-325 | ✔ | 99%+ | |||||||||||||||||
| Autophinib |
+++
Autophagy, IC50: 40 nM |
99% | |||||||||||||||||
| Lys05 | ✔ | 99%+ | |||||||||||||||||
| 1. 鼠标悬停在“+”上可以显示相关IC50的具体数值。"+"越多,抑制作用越强。2. "✔"表示该化合物对相应的亚型有抑制作用,但抑制强度暂时没有相关数据。 | |||||||||||||||||||
| 靶点 |
|
| 描述 | Hot shock protein 70(HSP70) is an ATP-dependent chaperone that can be induced by cellular stress and its aberrant activation is commonly observed in various malignancies. Pifithrin-μ is an inhibitor of inducible HSP70. It strongly inhibited cell viability with IC50 values of 2.5, 6.1, 4.4, 6.1, 12.7, 8.4 and 11.2 μM in NALM-6, TOM-1, BE-13, Jurkat, KG-1a, K562 and K562-r cells, respectively. In NALM-6 and KG-1a cell lines, incubation with Pifithrin-μ (4 and 5 μM for NALM-6; 40 and 60 μM for KG-1a) for 24h caused a remarkably reduced proportion of cells in S phase. Around 22% of NALM-6 cells were observed in the sub-G0/1 fraction after incubation with 5μM Pifithrin-μ, while only 2% of KG-1a cells were within this fraction after 60 μM Pifithrin-μ treatment. Incubation of NALM-6 cells with Pifithrin-μ at 4, 5 and 6.5 μM resulted in 34, 59 and 80% apoptotic cells above spontaneous apoptosis, respectively. Moreover, the intracellular AKT and ERK1/2 levels in NALM-6 cells was decreased by 10-h incubation of 10μM Pifithrin-μ[3]. In nude mice inoculated with human pancreatic cancer MiaPaca-2 cells, intraperitoneal injection with Pifithrin-μ (25mg/kg, 100μL) significantly enhanced the inhibitory effect of TRAIL on MiaPaca-2 tumor growth[4]. |
| Concentration | Treated Time | Description | References | |
| HepG2 cells | 5 µM | 1 hour | Pretreatment with Pifithrin-μ significantly alleviated GOX-induced mitochondrial dysfunction, including the loss of mitochondrial membrane potential, mitochondrial swelling, and the decrease in ATP levels. | Int J Biol Sci. 2016 Jan 1;12(2):198-209. |
| BCBL1 PEL cells | 20 µM | 12-48 hours | PES treatment increased cell death between 12 and 48 hours in both BC3 and BCBL1 cells, indicating time-dependent cytotoxicity. | Cell Death Dis. 2013 Jul 18;4(7):e730. |
| BC3 PEL cells | 10-30 µM | 24 hours | PES induced a dose-dependent cytotoxic effect in BC3 and BCBL1 PEL cells, leading to lysosome membrane permeabilization, relocation of cathepsin D to the cytosol, Bid cleavage, mitochondrial depolarization, and ultimately programmed cell death. | Cell Death Dis. 2013 Jul 18;4(7):e730. |
| SNU886 cells | 5 µM | 24 hours | Pifithrin-μ disrupted the interaction between CREB1 and CREBBP, reduced the mRNA levels of CREB1 target genes, and suppressed SESN3 expression, thereby enhancing sorafenib-induced cell death. | Cell Death Dis. 2025 Jan 26;16(1):42. |
| HCCLM3 cells | 10 µM | 24 hours | Pifithrin-μ inhibited HSP70 to reduce the transcriptional activity of CREB1 and the expression of SESN3, consequently enhancing sorafenib-induced ferroptosis in mTOR-activated liver cancer cells. | Cell Death Dis. 2025 Jan 26;16(1):42. |
| KG-1a (AML) | 0.5 to 100 µM | 48 hours | PFT-μ significantly inhibited cell viability at low micromolar concentrations in all cell lines tested, with IC50 values ranging from 2.5 to 12.7 μM, and was highly active in primary AML blasts with a median IC50 of 8.9 μM. PFT-μ induced apoptosis and cell cycle arrest in a dose-dependent manner in AML and ALL. | Blood Cancer J. 2011 Jul;1(7):e28. |
| NALM-6 (B-precursor ALL) | 0.5 to 100 µM | 48 hours | PFT-μ significantly inhibited the viability of NALM-6 cells, with an IC50 value of 2.5 μM. PFT-μ led to an increase in the active form of caspase-3 and reduced intracellular concentrations of AKT and ERK1/2. | Blood Cancer J. 2011 Jul;1(7):e28. |
| TOM-1 (B-precursor ALL; BCR-ABL positive) | 0.5 to 100 µM | 48 hours | PFT-μ significantly inhibited the viability of TOM-1 cells, with an IC50 value of 6.1 μM. PFT-μ enhanced the cytotoxicity of cytarabine, 17-AAG, SAHA, and sorafenib in TOM-1 cells. | Blood Cancer J. 2011 Jul;1(7):e28. |
| HONE1/Akata cells | 40 µM | 48 hours | PES significantly decreased the expression of EBNA1, independent of effects on EBNA1 transcription or proteasomal degradation. | Cell Death Dis. 2018 Jun 29;9(7):734. |
| HK1/Akata cells | 40 µM | 48 hours | PES significantly decreased the expression of EBNA1, independent of effects on EBNA1 transcription or proteasomal degradation. | Cell Death Dis. 2018 Jun 29;9(7):734. |
| B95-8 cells | 10 µM | 48 hours | PES significantly decreased the expression of EBNA1, independent of effects on EBNA1 transcription or proteasomal degradation. | Cell Death Dis. 2018 Jun 29;9(7):734. |
| Administration | Dosage | Frequency | Description | References | ||
| BALB/c Nude mice | Subcutaneous xenograft model | Intraperitoneal injection (Pifithrin-μ), Oral administration (sorafenib) | 10 mg/kg | Every other day, until the end of the experiment | Combined treatment of Pifithrin-μ and sorafenib significantly inhibited tumor growth in mTOR-activated liver cancer cells, reduced tumor volume and weight, and had no significant impact on the body weight of mice. | Cell Death Dis. 2025 Jan 26;16(1):42. |
| WT and Traf6−/− mice | Traf6−/− mice | Intraperitoneal injection | 10 mg/kg | Every other day for one week | Pifithrin-μ reversed the spontaneous apoptosis in Traf6?/? thymus, while pifithrin-α did not have this effect | Mol Cell. 2016 Nov 17;64(4):803-814 |
| BALB/c Nude mice | HONE1/Akata cell-induced tumor model | Intraperitoneal injection | 8 mg/kg | Once daily for 5 consecutive days | PES significantly inhibited the growth of tumors induced by HONE1/Akata cells and reduced the expression of EBNA1 in tumor tissues. | Cell Death Dis. 2018 Jun 29;9(7):734. |
| C57BL/6J mice | Cisplatin-induced cognitive impairment model | Intraperitoneal injection | 8 mg/kg | Once daily for two 5-day cycles | PFT-μ completely prevented cisplatin-induced cognitive impairment and associated structural changes in the brain, including loss of white matter integrity and neurogenic areas. | Cancer Res. 2017 Feb 1;77(3):742-752 |
| Dose | Mice: 1 mg/kg or 5 mg/kg[3] (i.p.), 40 mg/kg[2] (i.p.) |
| Administration | i.p. |
| 计算器 | ||||
| 存储液制备 | ![]() |
1mg | 5mg | 10mg |
|
1 mM 5 mM 10 mM |
5.52mL 1.10mL 0.55mL |
27.59mL 5.52mL 2.76mL |
55.18mL 11.04mL 5.52mL |
|
| CAS号 | 64984-31-2 |
| 分子式 | C8H7NO2S |
| 分子量 | 181.21 |
| SMILES Code | O=S(C#CC1=CC=CC=C1)(N)=O |
| MDL No. | MFCD00181531 |
| 别名 | 2-Phenylethynesulfonamide; PFTμ; PFT-µ; Pifithrin-µ; NSC 303580 |
| 运输 | 蓝冰 |
| InChI Key | ZZUZYEMRHCMVTB-UHFFFAOYSA-N |
| Pubchem ID | 327653 |
| 存储条件 |
In solvent -20°C: 3-6个月 -80°C: 12个月 Pure form Sealed in dry, 2-8°C |
| 溶解方案 |
DMSO: 105 mg/mL(579.43 mM),配合低频超声助溶,注意:DMSO长时间开封后,会吸水并导致溶解能力下降,请避免使用长期开封的DMSO 以下溶解方案都请先按照体外实验的方式配制澄清的储备液,再依次添加助溶剂: ——为保证实验结果的可靠性,澄清的储备液可以根据储存条件,适当保存;体内实验的工作液,建议现用现配,当天使用; 以下溶剂前显示的百分比是指该溶剂在终溶液中的体积占比;如在配制过程中出现沉淀、析出现象,可以通过加热和/或超声的方式助溶
|
沪公网安备 31011702889066号
沪ICP备2024050318号-1